Showing 321 - 340 results of 16,729 for search '(( 50 ((ng decrease) OR (teer decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 0.51s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326
  7. 327

    Longer <i>L</i><sub><i>h</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers. by Maral Budak (6680351)

    Published 2021
    “…<p>(A) Sound-evoked CAPs of SGN fiber populations of varying heminode length <i>L</i><sub><i>h</i></sub> at 70dB SPL, averaged over 50 simulations. …”
  8. 328

    Longer <i>L</i><sub><i>u</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers. by Maral Budak (6680351)

    Published 2021
    “…<p>(A) Sound-evoked CAPs of SGN fiber populations with varying unmyelinated segment length <i>L</i><sub><i>u</i></sub> at 70dB SPL, averaged over 50 simulations. …”
  9. 329
  10. 330

    DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx by Taotao Liang (9944552)

    Published 2022
    “…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  17. 337

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  18. 338
  19. 339
  20. 340